When we think about expedited reporting of adverse events, the number 15 usually comes to mind first. It is the industry default: serious reports generally go out within 15 calendar days, and non-serious ones within 90.

But that word “generally” hides a lot of complexity. While the 15-day rule is the golden standard in major ICH regions like the US, EU, and Japan, it is far from universal. The asymmetry in global reporting requirements is a significant challenge for Pharmacovigilance teams trying to maintain a single global standard.

The 15-Day Myth: You shouldn’t be surprised to find regulatory agencies that demand data much faster than the standard two-week window.

• Brazil (ANVISA): Serious cases must be reported within 10 days, not 15. This five-day difference often catches global teams off guard.
• China (NMPA): While standard serious cases follow the 15-day rule, deaths or “cluster events” must be reported immediately (often interpreted as within 24 hours).
• Veterinary Products: For the USFDA, serious unexpected reports for animal products also hit that 15-day mark.

Then you have the “Day 0” nuances. In the US and EU, the clock starts when anyone in the company (or a vendor) hears about the event. In Japan, strict language requirements mean you need to translate narratives into Japanese within that same window, adding a massive operational layer to the timeline.

Calendar vs. Working Days: Most of the world operates on “Calendar Days”, meaning weekends count. However, a few jurisdictions still cling to the concept of “Working Days,” creating a nightmare for automated scheduling systems that need to account for local public holidays.

The Non-Serious & Aggregate Gap: The asymmetry gets wider when we look at non-serious cases and aggregate reports:

• EU & UK: Non-serious cases are typically due in 90 days.
• USA: These are generally rolled into periodic reports (PADER/PAER) rather than individual expedited submissions.
• Canada: Often not required individually, just in annual reports.

For aggregate safety reports (PSURs), most countries have adopted the ICH E2C-R2 timelines: 70 days for intervals under a year, and 90 days for anything longer. But again, exceptions rule:

• India & South Africa: Periodic reports are often due within 30 calendar days.
• USA: Quarterly PADERs are strictly 30 days.
• Zimbabwe: While they follow ICH timelines generally, ad-hoc PSURs must be turned around in 30 days.

The RMP & Device Variable: Timelines for submitting updated Risk Management Plans (RMPs) remain a grey area. Most guidelines don’t explicitly specify when an update must be filed, leaving the Marketing Authorization Holder (MAH) to guess: Do we hold off? Submit everywhere at once? Ask the agency?

Add in medical device vigilance and cosmetovigilance, which have entirely different reporting clocks, and the landscape becomes chaotic.

The Path Forward: The ultimate goal is patient safety through timely data visibility. However, the current patchwork of 10-day, 15-day, and immediate deadlines makes administrative efficiency difficult. Harmonizing these timelines wouldn’t just make life easier for the industry; it would ensure that safety data flows consistently to regulators, rather than getting stuck in a compliance bottleneck.